Evidence map›Paper›PMID 33096640›Full record

ArticleBiomedicines2020

Anti-Inflammatory Effects of M-MSCs in DNCB-Induced Atopic Dermatitis Mice.

Bokyeong Ryu, Jieun Baek, Hana Kim, Ji-Heon Lee, Jin Kim, Young-Hoon Jeong, Seul-Gi Lee, Kyu-Ree Kang, Min-Seok Oh, Eun-Young Kim and 2 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Bokyeong RyuDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea.ORCID 0000-0001-8060-0601
Jieun BaekDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Hana KimDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Ji-Heon LeeDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Jin KimDepartment of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea.
Young-Hoon JeongDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Seul-Gi LeeDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Kyu-Ree KangDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Min-Seok OhDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Eun-Young KimMireacellbio Co., Ltd., Seoul 04795, Korea.ORCID 0000-0001-6299-6876
C-Yoon KimDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Hyung Min ChungDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Konkuk University · KRSeoul National University · KRKorea Advanced Institute of Science and Technology · KR

Funding

BK21 plus program -National Research Foundation of Korea 2015-M3A9C7030091National Research Foundation of Korea 2018R1C1B6007354
6 · The paper itself

Abstract

Atopic dermatitis (AD) is an inflammatory skin disease caused by an imbalance between Th1 and Th2 cells. AD patients suffer from pruritus, excessive dryness, red or inflamed skin, and complications such as sleep disturbances and depression. Although there are currently many AD treatments available there are insufficient data on their long-term stability and comparative effects. Moreover, they have limitations due to various side effects. Multipotent mesenchymal stem cells (M-MSCs) might have potential for next-generation AD therapies. MSCs are capable of immune function regulation and local inflammatory response inhibition. M-MSCs, derived from human embryonic stem cells (hESC), additionally have a stable supply. In L507 antibody array, M-MSCs generally showed similar tendencies to bone marrow-derived mesenchymal stem cells (BM-MSCs), although the immunoregulatory function of M-MSCs seemed to be superior to BM-MSCs. Based on the characteristics of M-MSCs on immunoregulatory functions, we tested a M-MSC conditioned media concentrate (MCMC) in mice with AD lesions on their dorsal skin. MCMC significantly decreased RNA expression levels of inflammatory cytokines in the mouse dorsal skin. It also suppressed serum IgE levels. In addition, significant histopathologic alleviation was identified. In conclusion, secretions of M-MSCs have the potential to effectively improve AD-related inflammatory lesions. M-MSCs showed potential for use in next-generation AD treatment.

Indexed as

atopic dermatitis (AD)embryonic stem cell (ESC)inflammationmesenchymal stem cell (MSC)treatment

Identifiers

PMID33096640
PMCPMC7589030
OpenAlexW3094630608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.